Combination of losartan with pirfenidone: a protective anti-fibrotic against pulmonary fibrosis induced by bleomycin in rats
Abstract Pirfenidone (PFD), one acceptable medication for treating idiopathic pulmonary fibrosis (IPF), is not well tolerated by patients at full doses. Hence, employing of some approaches such as combination therapy may be applicable for increasing therapeutic efficacy of PFD. Losartan (LOS), an an...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-04-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-59395-8 |
| _version_ | 1797199474160828416 |
|---|---|
| author | Arian Amirkhosravi Maryamossadat Mirtajaddini Goki Mahmoud Reza Heidari Somayyeh Karami-Mohajeri Maryam Iranpour Maryam Torshabi Mitra Mehrabani Ali Mandegary Mehrnaz Mehrabani |
| author_facet | Arian Amirkhosravi Maryamossadat Mirtajaddini Goki Mahmoud Reza Heidari Somayyeh Karami-Mohajeri Maryam Iranpour Maryam Torshabi Mitra Mehrabani Ali Mandegary Mehrnaz Mehrabani |
| author_sort | Arian Amirkhosravi |
| collection | DOAJ |
| description | Abstract Pirfenidone (PFD), one acceptable medication for treating idiopathic pulmonary fibrosis (IPF), is not well tolerated by patients at full doses. Hence, employing of some approaches such as combination therapy may be applicable for increasing therapeutic efficacy of PFD. Losartan (LOS), an angiotensin II receptor antagonist, could be a suitable candidate for combination therapy because of its stabilizing effect on the pulmonary function of IPF patients. Therefore, this study aimed to investigate the effects of LOS in combination with PFD on bleomycin (BLM)-induced lung fibrosis in rats. BLM-exposed rats were treated with LOS alone or in combination with PFD. The edema, pathological changes, level of transforming growth factor-β (TGF-β1), collagen content, and oxidative stress parameters were assessed in the lung tissues. Following BLM exposure, the inflammatory response, collagen levels, and antioxidant markers in rat lung tissues were significantly improved by PFD, and these effects were improved by combination with LOS. The findings of this in vivo study suggest that the combined administration of PFD and LOS may provide more potent protection against IPF than single therapy through boosting its anti-inflammatory, anti-fibrotic, and anti-oxidant effects. These results hold promise in developing a more effective therapeutic strategy for treating of lung fibrosis. |
| first_indexed | 2024-04-24T07:16:19Z |
| format | Article |
| id | doaj.art-7357ec8b222d40f2906d5888444dbadc |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-24T07:16:19Z |
| publishDate | 2024-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-7357ec8b222d40f2906d5888444dbadc2024-04-21T11:17:38ZengNature PortfolioScientific Reports2045-23222024-04-0114111010.1038/s41598-024-59395-8Combination of losartan with pirfenidone: a protective anti-fibrotic against pulmonary fibrosis induced by bleomycin in ratsArian Amirkhosravi0Maryamossadat Mirtajaddini Goki1Mahmoud Reza Heidari2Somayyeh Karami-Mohajeri3Maryam Iranpour4Maryam Torshabi5Mitra Mehrabani6Ali Mandegary7Mehrnaz Mehrabani8Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical SciencesPhysiology Research Center, Institute of Neuropharmacology, Kerman University of Medical SciencesDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, Kerman University of Medical SciencesDepartment of Toxicology and Pharmacology, Faculty of Pharmacy, Kerman University of Medical SciencesDepartment of Pathology, Pathology and Stem Cell Research Center, Faculty of Medicine, Kerman University of Medical SciencesDepartment of Dental Biomaterials, School of Dentistry, Shahid Beheshti University of Medical SciencesHerbal and Traditional Medicines Research Center, Kerman University of Medical SciencesPhysiology Research Center, Institute of Neuropharmacology, Kerman University of Medical SciencesPhysiology Research Center, Institute of Neuropharmacology, Kerman University of Medical SciencesAbstract Pirfenidone (PFD), one acceptable medication for treating idiopathic pulmonary fibrosis (IPF), is not well tolerated by patients at full doses. Hence, employing of some approaches such as combination therapy may be applicable for increasing therapeutic efficacy of PFD. Losartan (LOS), an angiotensin II receptor antagonist, could be a suitable candidate for combination therapy because of its stabilizing effect on the pulmonary function of IPF patients. Therefore, this study aimed to investigate the effects of LOS in combination with PFD on bleomycin (BLM)-induced lung fibrosis in rats. BLM-exposed rats were treated with LOS alone or in combination with PFD. The edema, pathological changes, level of transforming growth factor-β (TGF-β1), collagen content, and oxidative stress parameters were assessed in the lung tissues. Following BLM exposure, the inflammatory response, collagen levels, and antioxidant markers in rat lung tissues were significantly improved by PFD, and these effects were improved by combination with LOS. The findings of this in vivo study suggest that the combined administration of PFD and LOS may provide more potent protection against IPF than single therapy through boosting its anti-inflammatory, anti-fibrotic, and anti-oxidant effects. These results hold promise in developing a more effective therapeutic strategy for treating of lung fibrosis.https://doi.org/10.1038/s41598-024-59395-8Idiopathic pulmonary fibrosisOxidative stressCombination therapyBleomycinPirfenidoneLosartan |
| spellingShingle | Arian Amirkhosravi Maryamossadat Mirtajaddini Goki Mahmoud Reza Heidari Somayyeh Karami-Mohajeri Maryam Iranpour Maryam Torshabi Mitra Mehrabani Ali Mandegary Mehrnaz Mehrabani Combination of losartan with pirfenidone: a protective anti-fibrotic against pulmonary fibrosis induced by bleomycin in rats Scientific Reports Idiopathic pulmonary fibrosis Oxidative stress Combination therapy Bleomycin Pirfenidone Losartan |
| title | Combination of losartan with pirfenidone: a protective anti-fibrotic against pulmonary fibrosis induced by bleomycin in rats |
| title_full | Combination of losartan with pirfenidone: a protective anti-fibrotic against pulmonary fibrosis induced by bleomycin in rats |
| title_fullStr | Combination of losartan with pirfenidone: a protective anti-fibrotic against pulmonary fibrosis induced by bleomycin in rats |
| title_full_unstemmed | Combination of losartan with pirfenidone: a protective anti-fibrotic against pulmonary fibrosis induced by bleomycin in rats |
| title_short | Combination of losartan with pirfenidone: a protective anti-fibrotic against pulmonary fibrosis induced by bleomycin in rats |
| title_sort | combination of losartan with pirfenidone a protective anti fibrotic against pulmonary fibrosis induced by bleomycin in rats |
| topic | Idiopathic pulmonary fibrosis Oxidative stress Combination therapy Bleomycin Pirfenidone Losartan |
| url | https://doi.org/10.1038/s41598-024-59395-8 |
| work_keys_str_mv | AT arianamirkhosravi combinationoflosartanwithpirfenidoneaprotectiveantifibroticagainstpulmonaryfibrosisinducedbybleomycininrats AT maryamossadatmirtajaddinigoki combinationoflosartanwithpirfenidoneaprotectiveantifibroticagainstpulmonaryfibrosisinducedbybleomycininrats AT mahmoudrezaheidari combinationoflosartanwithpirfenidoneaprotectiveantifibroticagainstpulmonaryfibrosisinducedbybleomycininrats AT somayyehkaramimohajeri combinationoflosartanwithpirfenidoneaprotectiveantifibroticagainstpulmonaryfibrosisinducedbybleomycininrats AT maryamiranpour combinationoflosartanwithpirfenidoneaprotectiveantifibroticagainstpulmonaryfibrosisinducedbybleomycininrats AT maryamtorshabi combinationoflosartanwithpirfenidoneaprotectiveantifibroticagainstpulmonaryfibrosisinducedbybleomycininrats AT mitramehrabani combinationoflosartanwithpirfenidoneaprotectiveantifibroticagainstpulmonaryfibrosisinducedbybleomycininrats AT alimandegary combinationoflosartanwithpirfenidoneaprotectiveantifibroticagainstpulmonaryfibrosisinducedbybleomycininrats AT mehrnazmehrabani combinationoflosartanwithpirfenidoneaprotectiveantifibroticagainstpulmonaryfibrosisinducedbybleomycininrats |